Your browser doesn't support javascript.
loading
Trajectories of Seroprevalence and Neutralizing Activity of Antibodies against SARS-CoV-2 in Southern Switzerland between July 2020 and July 2021: An Ongoing, Prospective Population-Based Cohort Study.
Amati, Rebecca; Piumatti, Giovanni; Franscella, Giovanni; Buttaroni, Peter; Camerini, Anne-Linda; Corna, Laurie; Levati, Sara; Fadda, Marta; Fiordelli, Maddalena; Annoni, Anna Maria; Bezani, Kleona; Amendola, Antonio; Fragoso Corti, Cristina; Sabatini, Serena; Kaufmann, Marco; Frei, Anja; Puhan, Milo Alan; Crivelli, Luca; Albanese, Emiliano.
Afiliação
  • Amati R; Institute of Public Health, Faculty of Biomedical Sciences, Università della Svizzera italiana, 6900 Lugano, Switzerland.
  • Piumatti G; Fondazione Agnelli, 10125 Turin, Italy.
  • Franscella G; Institute of Public Health, Faculty of Biomedical Sciences, Università della Svizzera italiana, 6900 Lugano, Switzerland.
  • Buttaroni P; Faculty of Informatics, Università della Svizzera italiana, 6900 Lugano, Switzerland.
  • Camerini AL; Institute of Public Health, Faculty of Biomedical Sciences, Università della Svizzera italiana, 6900 Lugano, Switzerland.
  • Corna L; Department of Business Economics, Health and Social Care, University of Applied Sciences and Arts of Southern Switzerland, 6928 Manno, Switzerland.
  • Levati S; Department of Business Economics, Health and Social Care, University of Applied Sciences and Arts of Southern Switzerland, 6928 Manno, Switzerland.
  • Fadda M; Institute of Public Health, Faculty of Biomedical Sciences, Università della Svizzera italiana, 6900 Lugano, Switzerland.
  • Fiordelli M; Institute of Public Health, Faculty of Biomedical Sciences, Università della Svizzera italiana, 6900 Lugano, Switzerland.
  • Annoni AM; Department of Health Sciences, University of Lucerne, 6002 Lucerne, Switzerland.
  • Bezani K; Institute of Public Health, Faculty of Biomedical Sciences, Università della Svizzera italiana, 6900 Lugano, Switzerland.
  • Amendola A; Institute of Public Health, Faculty of Biomedical Sciences, Università della Svizzera italiana, 6900 Lugano, Switzerland.
  • Fragoso Corti C; Department of Business Economics, Health and Social Care, University of Applied Sciences and Arts of Southern Switzerland, 6928 Manno, Switzerland.
  • Sabatini S; Institute of Microbiology, University of Applied Sciences and Arts of Southern Switzerland, 6501 Bellinzona, Switzerland.
  • Kaufmann M; Institute of Public Health, Faculty of Biomedical Sciences, Università della Svizzera italiana, 6900 Lugano, Switzerland.
  • Frei A; Epidemiology, Biostatistics and Prevention Institute, University of Zurich, 8001 Zurich, Switzerland.
  • Puhan MA; Epidemiology, Biostatistics and Prevention Institute, University of Zurich, 8001 Zurich, Switzerland.
  • Crivelli L; Epidemiology, Biostatistics and Prevention Institute, University of Zurich, 8001 Zurich, Switzerland.
  • Albanese E; Institute of Public Health, Faculty of Biomedical Sciences, Università della Svizzera italiana, 6900 Lugano, Switzerland.
  • On Behalf Of The Corona Immunitas Ticino Study Group; Department of Business Economics, Health and Social Care, University of Applied Sciences and Arts of Southern Switzerland, 6928 Manno, Switzerland.
Article em En | MEDLINE | ID: mdl-36834397
ABSTRACT

OBJECTIVES:

The COVID-19 pandemic continues, and evidence on infection- and vaccine-induced immunity is key. We assessed COVID-19 immunity and the neutralizing antibody response to virus variants across age groups in the Swiss population. STUDY

DESIGN:

We conducted a cohort study in representative community-dwelling residents aged five years or older in southern Switzerland (total population 353,343), and we collected blood samples in July 2020 (in adults only, N = 646), November-December 2020 (N = 1457), and June-July 2021 (N = 885).

METHODS:

We used a previously validated Luminex assay to measure antibodies targeting the spike (S) and the nucleocapsid (N) proteins of the virus and a high-throughput cell-free neutralization assay optimized for multiple spike protein variants. We calculated seroprevalence with a Bayesian logistic regression model accounting for the population's sociodemographic structure and the test performance, and we compared the neutralizing activity between vaccinated and convalescent participants across virus variants.

RESULTS:

The overall seroprevalence was 7.8% (95% CI 5.4-10.4) by July 2020 and 20.2% (16.4-24.4) by December 2020. By July 2021, the overall seroprevalence increased substantially to 72.5% (69.1-76.4), with the highest estimates of 95.6% (92.8-97.8) among older adults, who developed up to 10.3 more antibodies via vaccination than after infection compared to 3.7 times more in adults. The neutralizing activity was significantly higher for vaccine-induced than infection-induced antibodies for all virus variants (all p values < 0.037).

CONCLUSIONS:

Vaccination chiefly contributed to the reduction in immunonaive individuals, particularly those in older age groups. Our findings on the greater neutralizing activity of vaccine-induced antibodies than infection-induced antibodies are greatly informative for future vaccination campaigns.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: SARS-CoV-2 / COVID-19 Tipo de estudo: Etiology_studies / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Aged / Humans País/Região como assunto: Europa Idioma: En Revista: Int J Environ Res Public Health Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Suíça

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: SARS-CoV-2 / COVID-19 Tipo de estudo: Etiology_studies / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Aged / Humans País/Região como assunto: Europa Idioma: En Revista: Int J Environ Res Public Health Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Suíça